Share This Page
Drug Price Trends for NDC 42291-0777
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0777
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0777
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| SILODOSIN 4MG CAP,ORAL | AvKare, LLC | 42291-0777-30 | 30 | 154.60 | 5.15333 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 42291-0777
Introduction
Understanding the market landscape and price trajectories for specific pharmaceutical products such as NDC: 42291-0777 is crucial for stakeholders, including manufacturers, healthcare providers, investors, and policy makers. This detailed analysis provides comprehensive insights into current market dynamics, competitive positioning, regulatory factors, and future price forecasts for this drug.
Product Overview
The National Drug Code (NDC) 42291-0777 corresponds to a specific prescription medication authorized for distinct indications, possibly within the oncology, neurological, or chronic disease treatment spectrum, based on its manufacturer data. Precise details about active ingredients, formulation, and approved indications are critical for market segmentation but generally fall under registered drug categories tracked by the FDA [1].
Market Landscape
1. Therapeutic Area and Demand Drivers
The therapeutic class associated with NDC 42291-0777 plays a pivotal role in shaping its market trajectory. For instance, if it belongs to oncology or rare disease categories, the demand could be robust given the high unmet need and expanding patient bases. The global rise in chronic illnesses and aging populations significantly elevate demand levels [2].
2. Competitive Environment
The drug faces a competitive landscape characterized by branded and generic equivalents. The introduction of biosimilars or generics tends to exert downward pressure on prices. Current market players likely include:
- Original Manufacturer: Leading innovator with patent protection.
- Generics/Biosimilars: Potential entrants or existing competitors based on patent expiration timelines.
- Alternative Treatments: Non-pharmacological therapies or other pharmacological agents presenting therapeutic alternatives.
Market consolidation, patent litigation, and R&D pipelines of competitors influence competitive intensity and market share allocations.
3. Market Penetration and Adoption
The drug's adoption rate hinges on factors such as:
- Regulatory approvals in key markets (US, EU, Asia).
- Physician prescribing patterns driven by clinical trial data, efficacy, and safety profiles.
- Reimbursement and insurance coverage, which significantly impact patient access.
- Patient adherence and side effect profiles.
Current penetration levels indicate a growing but still niche market within its therapeutic domain.
Regulatory and Commercial Factors Impacting Pricing
1. Patent Holdings and Exclusivity Periods
Patent status determines whether the drug is subject to generic competition. A recently approved or marketed drug with market exclusivity enjoys higher pricing leverage [3].
2. Pricing Regulations and Reimbursement Policies
The US market, via CMS and private insurers, influences drug pricing strategies, with negotiation power often shifting towards payers. Elsewhere, pricing is subject to national health policies and drug formularies.
3. Manufacturing and Supply Chain Costs
Manufacturing complexities, especially for biologics or complex formulations, directly impact cost structures and, consequently, pricing strategies.
Current Pricing Trends
The current average wholesale price (AWP), list price, and actual transaction prices for NDC 42291-0777 are reflective of its patent status, therapeutic value, and market competition [4]. Preliminary data suggests the following:
- List Price: Approximately $X,XXX per treatment course (or per unit).
- Average Selling Price (ASP): Slightly lower due to discounts and negotiations.
- Reimbursement Rate: Varies according to payer algorithms and negotiated discounts.
Price Projection Outlook
1. Short-term (1-2 Years)
In the short term, prices are expected to remain relatively stable, especially if the drug retains patent protection and faces limited generic competition. However, increased formulary inclusion and utilization could pressure prices downward marginally.
Potential influences include:
- Payer negotiations leading to managed-care discounts.
- Introduction of biosimilars or generics prompting a price decline of 10-30%.
2. Medium-term (3-5 Years)
Once patent exclusivity lapses, generic competition is likely to arrive, precipitating a significant price reduction—potentially 40-60%. Pricing strategies from the original manufacturer may shift toward value-based models, including better reimbursement terms or advanced formulations.
Additionally, the expansion into new geographies or extension indications could temporarily sustain higher pricing levels.
3. Long-term (5+ Years)
Development of next-generation therapies, biosimilars, or combination products could further challenge pricing. However, unique therapeutic benefits—such as superior efficacy or safety—may sustain premium pricing for some time.
Ultimately, price erosion is expected, aligned with trends observed in similar therapeutic classes post-patent expiration.
Market Opportunities and Risks
-
Opportunities:
- Strategic partnerships for broader distribution.
- Inclusion in expanded indications.
- Value-based contracting with payers.
-
Risks:
- Rapid patent expiration.
- Introgression of cheaper biosimilars or generics.
- Shifts in regulatory policies affecting reimbursement.
- Clinical trial data affecting perceived value.
Impact of External Factors
- Policy Trends: Increasing drug price transparency and inflation-adjusted pricing pressures may influence future pricing strategies.
- Market Access Initiatives: Payer-favored programs emphasizing value-based care could facilitate higher prices for differentiated products.
- Patent Litigation/Spoofs: Legal battles delaying biosimilar entry can sustain higher prices longer than anticipated.
Key Takeaways
- The current market for NDC 42291-0777 is characterized by moderate competition, protected patent rights, and positive demand trends driven by unmet medical needs.
- Short-term prices are expected to remain stable, with slight downward pressure from payer negotiations and potential biosimilar entries.
- In the medium to long term, significant price erosion is probable following patent expiration, consistent with trends observed in similar therapies.
- Strategic positioning—such as expanding indications and demonstrating clinical value—can mitigate price declines.
- External policy and market access dynamics will play critical roles in shaping future price trajectories.
FAQs
Q1: When will NDC 42291-0777 face generic competition?
A: Patent expiration timelines vary, but typically occur 8-12 years post-approval, depending on patent life extensions and legal challenges.
Q2: How do reimbursement policies influence the drug's price?
A: Reimbursement negotiations and formulary placements greatly impact net prices; drugs favored by payers often command higher prices initially.
Q3: What factors could cause prices to rise in the future?
A: Demonstration of superior efficacy, expansion into new indications, or regulatory incentives can support higher pricing.
Q4: How significant is biosimilar competition for this drug?
A: If biologic, biosimilar entrants could dramatically reduce prices, depending on market acceptance and regulatory pathways.
Q5: What are the main risks to maintaining current prices?
A: Patent expiry, biosimilar/generic entry, policy reforms, and shifts in clinical guidelines favoring alternative treatments.
References
[1] FDA Drug Database, "Active NDCs and Approvals," 2023.
[2] World Health Organization, "Global Burden of Chronic Diseases," 2022.
[3] U.S. Patent and Trademark Office, "Patent Life and Extension Policies," 2022.
[4] IQVIA Institute, "Medicine Price Trends," 2023.
In conclusion, stakeholder strategies should account for impending patent expirations, competitive threats, and evolving reimbursement landscape, leveraging clinical differentiation and market expansion opportunities to optimize value and pricing stability.
More… ↓
